Emerging angiogenesis inhibitors for non-small cell lung cancer

References

• Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 183 countries. CA Cancer J Clin. 2018;68(6):394–424.
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miler KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68(1):7–30.
   PubMed Web of Science ®Google Scholar
• Ferlay J, Colombet M, Soerjomataram I, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries and 25 major cancers in 2018. Eur J Cancer. 2018;103:356–387.
   PubMed Web of Science ®Google Scholar
• Forman D, Bray F, Brewster D, et al. Cancer incidence in five continents. Lyon France: International Agency for Research on Cancer; 2014.
   Google Scholar
• Wahbah M, Boroumand N, Castro C, et al. Changing trends in the distribution of the histologic types of lung cancer: a review of 4,439 cases. Ann Diagn Pathol. 2007;11(2):89–96.
   PubMed Web of Science ®Google Scholar
• Planchard D, Popat S, Kerr K, et al. Metastatic non-small-cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29(suppl. 4):iv192–iv237.
   PubMed Web of Science ®Google Scholar
• Hanna N, Johnson D, Temin S, et al. Systemic therapy for stage IV non-small-cell lung cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2017;35(30):3484–3515.
   PubMed Web of Science ®Google Scholar
• Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol. 2005;23(5):1011–1027.
   PubMed Web of Science ®Google Scholar
• Betsholtz C, Karlsson L, Lindahl P. Developmental roles of platelet-derived growth factors. Bioessays. 2001;23(6):494–507.
   PubMed Web of Science ®Google Scholar
• Dong J, Grunstein J, Tejada M, et al. VEGF-null cells require PDGFR alpha signalling mediated stromal fibroblast recruitment for tumorigenesis. EMBO J. 2004;23(14):2800–2810.
   PubMed Web of Science ®Google Scholar
• Reinmuth N, Liu W, Jung YD, et al. Induction of VEGF in perivascular cells defines a potential paracrine mechanism for endothelial cell survival. FASEB J. 2001;15(7):1239–1241.
   PubMed Web of Science ®Google Scholar
• Gaur P, Bose D, Samuel S, et al. Targeting tumor angiogenesis. Semin Oncol. 2009;36(Suppl 1):S12–S19.
   PubMedGoogle Scholar
• Rajabi M, Mousa SA. The role of angiogenesis in cancer treatment. Biomedicines. 2017;5(2):34.
   PubMed Web of Science ®Google Scholar
• Risau W. Mechanisms of angiogenesis. Nature. 1997;386(6626):671–674.
   PubMed Web of Science ®Google Scholar
• Gasti G, Hermann T, Steurer M, et al. Angiogenesis as a target for tumor treatment. Oncology. 1997;54(3):177–184.
   PubMed Web of Science ®Google Scholar
• Sacco PC, Maione P, Rossi A, et al. New antiangiogenetic therapy beyond bevacizumab in the treatment of advanced non small cell lung cancer. Curr Pharm Des. 2015;21(32):4763–4772.
   PubMed Web of Science ®Google Scholar
• Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med. 1971;285(21):1182–1186.
   PubMed Web of Science ®Google Scholar
• Senger DR, Galli SJ, Dvorak AM, et al. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science. 1983;219(4587):983–985.
   PubMed Web of Science ®Google Scholar
• Leung DW, Cachianes G, Kuang WJ, et al. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science. 1989;246(4935):1306–1309.
   PubMed Web of Science ®Google Scholar
• Keck PJ, Hauser SD, Krivi G, et al. Vascular permeability factor, an endothelial cell mitogen related to PDGF. Science. 1989;246(4935):1309–1312.
   PubMed Web of Science ®Google Scholar
• Kim KJ, Li B, Winer J, et al. Inhibition of vascular endothelial growth factor induced angiogenesis suppresses tumour growth in vivo. Nature. 1993;362(6423):841–844.
   PubMed Web of Science ®Google Scholar
• Hurwitz H. Integrating the anti-VEGF-A humanized monoclonal antibody bevacizumab with chemotherapy in advanced colorectal cancer. Clin Colorectal Cancer. 2004;4(Suppl 2):S62–S68.
   PubMedGoogle Scholar
• Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006;355(24):2542–2550.
   PubMed Web of Science ®Google Scholar
• Schneider BP, Shen F, Miller KD. Pharmacogenetic biomarkers for the prediction of response to antiangiogenic treatment. Lancet Oncol. 2012;13(10):e427–e436.
   PubMed Web of Science ®Google Scholar
• Sandler AB, Kong G, Strickland D, et al. Treatment outcomes by tumor histology in Eastern Cooperative Group (ECOG) study E4599 of bevacizumab with paclitaxel/carboplatin for advanced non-small cell lung cancer (NSCLC). J Thorac Oncol. 2010;5(9):1416–1423.
   PubMed Web of Science ®Google Scholar
• Reck M, von Pawel J, Zatloukal P, et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: aVAil. J Clin Oncol. 2009;27(8):1227–1234.
   PubMed Web of Science ®Google Scholar
• Reck M, von Pawel J, Zatloukal P, et al. Overall survival with cisplatin/gemcitabine and bevacizumab or placebo as first-line therapy for non-squamous non-small cell lung cancer: results from a randomized phase III trial (AVAiL). Ann Oncol. 2010;21(9):1804–1809.
   PubMed Web of Science ®Google Scholar
• Johnson DH, Fehrenbacher L, Novotny WF, et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol. 2004;22(11):2184–2191.
   PubMed Web of Science ®Google Scholar
• Garon EB, Ciuleanu T, Arrieta O, et al. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. Lancet. 2014;384(9944):665–673.
   PubMed Web of Science ®Google Scholar
• Hilberg F, Roth GJ, Krssak M, et al. BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. Cancer Res. 2008;68(12):4774–4782.
   PubMed Web of Science ®Google Scholar
• Reck M, Kaiser R, Mellemgaard A, et al. Docetaxel plus nintedanib versus docetaxelplus placebo in patients with previously treated non-small-cell lung cancer (LUME-lung 1): a phase 3, double-blind, randomised controlled trial. Lancet Oncol. 2014;15(2):143–155.
   PubMed Web of Science ®Google Scholar
• Hanna NH, Kaiser R, Sullivan RN, et al. Nintedanib plus pemetrexed versus placebo plus pemetrexed in patients with relapsed or refractory, advanced non-small cell lung cancer (LUME-Lung 2): A randomized, double-blind, phase III trial. Lung Cancer. 2016;102:65–73.
   PubMed Web of Science ®Google Scholar
• Dowlati A, Gray R, Sandler AB, et al. Cell adhesion molecules, vascular endothelial growth factor, and basic fibroblast growth factor in patients with non-small cell lung cancer treated with chemotherapy with or without bevacizumab an Eastern Cooperative Oncology Group study. Clin Cancer Res. 2008;14(5):1407–1412.
   PubMed Web of Science ®Google Scholar
• Goulart B, Ramsey SD. A trial-based assessment of the cost-utility of bevacizumab and chemotherapy versus chemotherapy alone for advanced non-small cell lung cancer. Value Health. 2011;14(6):836–845.
   PubMed Web of Science ®Google Scholar
• Espinosa Bosch M, Asensi Diez R, García Agudo S, et al. Nintedanib in combination with docetaxel for second-line treatment of advanced non-small-cell lung cancer; GENESIS-SEFH drug evaluation report. Farm Hosp. 2016;40(4):316–327.
   PubMedGoogle Scholar
• Bustamante Alvarez JG, Gonzalez-Cao M, Karachaliou N, et al. Advances in immunotherapy for treatment of lung cancer. Cancer Biol Med. 2015;12(3):209–222.
   PubMed Web of Science ®Google Scholar
• Manzo A, Montanino A, Carillio G, et al. Angiogenesis Inhibitors in NSCLC. Int J Mol Sci. 2017;18(10):E2021.
   PubMed Web of Science ®Google Scholar
• Neal JW, Wakelee HA. Aflibercept in lung cancer. Expert Opin Biol Ther. 2013;13(1):115–120.
   PubMed Web of Science ®Google Scholar
• de Miguel D, Lemke J, Anel A, et al. Onto better TRAILs for cancer treatment. Cell Death Differ. 2016;23(5):733–747.
   PubMed Web of Science ®Google Scholar
• Ouyang X, Shi M, Jie F, et al. Phase III study of dulanermin (recombinant human tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand) combined with vinorelbine and cisplatin in patients with advanced non-small-cell lung cancer. Invest New Drugs. 2017;36(2):315–322.
   PubMed Web of Science ®Google Scholar
• Nishio M, Horiike A, Nokihara H, et al. Phase I study of the anti-MET antibody onartuzumab in patients with solid tumors and MET-positive lung cancer. Invest New Drugs. 2015;33(3):632–640.
   PubMed Web of Science ®Google Scholar
• Rolfo C, Van Der Steen N, Pauwels P, et al. Onartuzumab in lung cancer: the fall of Icarus?. Expert Rev Anticancer Ther. 2015;15(5):487–489.
   PubMed Web of Science ®Google Scholar
• Spigel DR, Edelman MJ, O’Byrne K, et al. Results from the phase III randomized trial of onartuzumab plus erlotinib versus erlotinib in previously treated stage IIIB or IV non-small-cell lung cancer: mETLung. J Clin Oncol. 2017;35(4):412–420.
   PubMed Web of Science ®Google Scholar
• Mita AC, Takimoto CH, Mita M, et al. Phase 1 study of AMG 386, a selective angiopoietin 1/2-neutralizing peptibody, in combination with chemotherapy in adults with advanced solid tumors. Clin Cancer Res. 2010;16(11):3044–3056.
   PubMed Web of Science ®Google Scholar
• King JW, Lee SM. Axitinib for the treatment of advanced non-small-cell lung cancer. Expert Opin Investig Drugs. 2013;22(6):765–773.
   PubMed Web of Science ®Google Scholar
• Yan J, Pang Y, Sheng J, et al. A novel synthetic compound exerts effective anti-tumour activity in vivo via the inhibition of tubulin polymerisation in A549 cells. Biochem Pharmacol. 2015;97(1):51–61.
   PubMed Web of Science ®Google Scholar
• Garon EB, Neidhart JD, Gabrail NY, et al. A randomized phase II trial of the tumor vascular disrupting agent CA4P (fosbretabulin tromethamine) with carboplatin, paclitaxel, and bevacizumab in advanced nonsquamous non-small-cell lung cancer. Onco Targets Ther. 2016;9:7275–7283.
   PubMed Web of Science ®Google Scholar
• Galustian C, Dalgleish A. Lenalidomide: a novel anticancer drug with multiple modalities. Expert Opin Pharmacother. 2009;10(1):125–133.
   PubMed Web of Science ®Google Scholar
• Corti A, Giovannini M, Belli C, et al. Immunomodulatory agents with antivascular activity in the treatment of non-small cell lung cancer: focus on TLR9 agonists, IMiDs and NGR-TNF. J Oncol. 2010;2010:732680.
   PubMedGoogle Scholar
• Kalmadi S, Davis M, Dowlati A, et al. Phase I trial of three-weekly docetaxel, carboplatin and oral lenalidomide (Revlimid) in patients with advanced solid tumors. Invest New Drugs. 2007;25(3):211–216.
   PubMed Web of Science ®Google Scholar
• Elli S, Stancanelli E, Handley PN, et al. Structural and conformational studies of the heparan sulfate mimetic PI-88. Glycobiology. 2018;28(10):731–740.
   PubMed Web of Science ®Google Scholar
• Podar K, Tonon G, Sattler M, et al. The small-molecule VEGF receptor inhibitor pazopanib (GW786034B) targets both tumor and endothelial cells in multiple myeloma. Proc Natl Acad Sci U S A. 2006;103(51):19478–19483.
   PubMed Web of Science ®Google Scholar
• Spigel DR, Burris HA 3rd, Greco FA, et al. Erlotinib plus either pazopanib or placebo in patients with previously treated advanced non-small cell lung cancer: a randomized, placebo-controlled phase 2 trial with correlated serum proteomic signatures. Cancer. 2018;124(11):2355–2364.
   PubMed Web of Science ®Google Scholar
• Besse B, Mazières J, Ribassin-Majed L, et al. Pazopanib or placebo in completely resected stage I NSCLC patients: results of the phase II IFCT-0703 trial. Ann Oncol. 2017;28(5):1078–1083.
   PubMed Web of Science ®Google Scholar
• Nassif E, Thibault C, Vano Y, et al. Sunitinib in kidney cancer: 10 years of experience and development. Expert Rev Anticancer Ther. 2017;17(2):129–142.
   PubMed Web of Science ®Google Scholar
• Mok T, Gorbunova V, Juhaszu E, et al. A correlative biomarker analysis of the combination of bevacizumab and carboplatin-based chemotherapy for advanced nonsquamous non-small-cell lung cancer: results of the phase II randomized ABIGAIL study (BO21015). J Thorac Oncol. 2014;9(6):848–855.
   PubMed Web of Science ®Google Scholar
• Pallaud C, Reck M, Juhaszu E, et al. Clinical genotyping and efficacy outcomes: exploratory biomarker data from the phase II ABIGAIL study of first-line bevacizumab plus chemotherapy in non-squamous non-small-cell lung cancer. Lung Cancer. 2014;86(1):67–72.
   PubMed Web of Science ®Google Scholar
• Khan KA, Kerbel RS. Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa. Nat Rev Clin Oncol. 2018;15(5):310–324.
   PubMed Web of Science ®Google Scholar
• Yang J, Yan J, Liu B. Targeting VEGF/VEGFR to modulate antitumor immunity. Front Immunol. 2018;9:978.
   PubMed Web of Science ®Google Scholar
• Socinski MA, Jotte RM, Cappuzzo F, et al. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N Engl J Med. 2018;378(24):2288–2301.
   PubMed Web of Science ®Google Scholar
• El Alaoui-Lasmaili K, Faivre B. Antiangiogenic therapy: markers of response “normalization” and resistance. Crit Rev Oncol Hematol. 2018;128:118–129.
   PubMed Web of Science ®Google Scholar
• Bronte G, Rolfo C, Giovannetti E. et al. Are erlotinib and gefitinib interchangeable, opposite or complementary for non-small cell lung cancer treatment? Biological, pharmacological and clinical aspects. Cri Rev Oncol Hematol. 2014;89(2):300–313.
   PubMed Web of Science ®Google Scholar